Normal view MARC view ISBD view

Palliative chemotherapy in carcinoma penis: does platinum and taxane combination holds a promise?

In Urology Annals
By: Patil VM.
Contributor(s): Joshi A | Bakshi G | Bhosale B | Muddu V | Noronha V | kprabhash1@gmail.com | Prabhash K.
Material type: materialTypeLabelArticleSeries: Vol 6 Issues 1.Publisher: 2014Description: 18-22.Subject(s): palliative | metastatic penile carcinoma | Chemotherapy | DDC classification: Online resources: Click here to access online In: Urology AnnalsSummary: Aim: To report safety and efficacy of chemotherapy incorporating the combination of paclitaxel and platinum in patients with advanced penile carcinoma. Materials and Methods: Retrospective analysis of patient with advanced penile carcinoma undergoing palliative chemotherapy with paclitaxel and platinum combination. The demographic profile, indication of treatment, chemotherapy details, toxicity and survival outcome were noted. Statistical analysis was done for estimation of progression free survival and overall survival. Factors affecting these outcomes were sought for. Results: Eighteen patients with a median age of 47.5 years (31-68 years) were offered palliative intent chemotherapy over a period of 2.5 years. ECOG performance was 1 in 12 patients (66.7%) and 2 in 6 patients(33.3%).The grade of tumor was poorly differentiated in 8 patients(44.4%), moderately differentiated in 5 (27.8%) and we1l differentiated in 5 patients(27.8%). Twelve patients had previous surgical treatment(66.7%), with 2
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
(Browse shelf) Available AR15547

Aim: To report safety and efficacy of chemotherapy incorporating the combination of paclitaxel and platinum
in patients with advanced penile carcinoma.
Materials and Methods: Retrospective analysis of patient with advanced penile carcinoma undergoing palliative chemotherapy with paclitaxel and platinum combination. The demographic profile, indication of
treatment, chemotherapy details, toxicity and survival outcome were noted. Statistical analysis was done for
estimation of progression free survival and overall survival. Factors affecting these outcomes were sought for.
Results: Eighteen patients with a median age of 47.5 years (31-68 years) were offered palliative intent chemotherapy over a period of 2.5 years. ECOG performance was 1 in 12 patients (66.7%) and 2 in 6 patients(33.3%).The grade of tumor was poorly differentiated in 8 patients(44.4%), moderately differentiated
in 5 (27.8%) and we1l differentiated in 5 patients(27.8%). Twelve patients had previous surgical treatment(66.7%),
with 2

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha